作者
Philippa B Mills, Emma J Footitt, Kevin A Mills, Karin Tuschl, Sarah Aylett, Sophia Varadkar, Cheryl Hemingway, Neil Marlow, Janet Rennie, Peter Baxter, Olivier Dulac, Rima Nabbout, William J Craigen, Bernhard Schmitt, François Feillet, Ernst Christensen, Pascale De Lonlay, Mike G Pike, M Imelda Hughes, Eduard A Struys, Cornelis Jakobs, Sameer M Zuberi, Peter T Clayton
发表日期
2010/7/1
期刊
Brain
卷号
133
期号
7
页码范围
2148-2159
出版商
Oxford University Press
简介
Pyridoxine-dependent epilepsy was recently shown to be due to mutations in the ALDH7A1 gene, which encodes antiquitin, an enzyme that catalyses the nicotinamide adenine dinucleotide-dependent dehydrogenation of l-α-aminoadipic semialdehyde/l1-piperideine 6-carboxylate. However, whilst this is a highly treatable disorder, there is general uncertainty about when to consider this diagnosis and how to test for it. This study aimed to evaluate the use of measurement of urine l-α-aminoadipic semialdehyde/creatinine ratio and mutation analysis of ALDH7A1 (antiquitin) in investigation of patients with suspected or clinically proven pyridoxine-dependent epilepsy and to characterize further the phenotypic spectrum of antiquitin deficiency. Urinary l-α-aminoadipic semialdehyde concentration was determined by liquid chromatography tandem mass spectrometry. When this was above the normal range, DNA …
引用总数
200920102011201220132014201520162017201820192020202120222023202413213027221821151913232618166
学术搜索中的文章